AlloRx

Phase 1Cell therapy

TThe Foundation for Orthopaedics and Regenerative Medicine

AlloRx is one of 221 biologic programs targeting Interstitial Cystitis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

220

Competitors

Pipeline

Status by Indication[3][1]

Indication

Interstitial CystitisActive, not recruiting

Tourette SyndromeActive, not recruiting

Systemic SclerosisActive, not recruiting

OsteoporosisActive, not recruiting

Skin UlcerActive, not recruiting

Heart DiseaseActive, not recruiting

AutismActive, not recruiting

Interstitial CystitisPhase 1

Active, not recruiting

Tourette SyndromePhase 1

Active, not recruiting

Systemic SclerosisPhase 1

Active, not recruiting

OsteoporosisPhase 1

Active, not recruiting

Skin UlcerPhase 1

Active, not recruiting

Heart DiseasePhase 1

Active, not recruiting

AutismPhase 1

Active, not recruiting

Competition

Competitive Landscape

172 competitors in Osteoporosis

#DrugCompanyPhaseTrials

Boniva

CConrado Roberto Hoffmann Filho

Phase 3

26 2

Actonel

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 3

16 3

One-Alpha

Roche

Phase 3

3 4

Livial

Pfizer

Phase 3

1 5

Depo-Provera

Tymlos

2 7

Glucophage

EMD Serono

Phase 3

1 8

Oxycodone IR

Johnson & Johnson

Phase 3

1 9

Bazedoxifene Acetate

Pfizer

Phase 3

2 10

Ibandronic Acid

Roche

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Recruiting

Mesenchymal Stem Cell

NCT05003934

Q4 2026

Phase 1Recruiting

Systemic Sclerosis

NCT05016804

Q4 2027

Phase 1Recruiting

Mesenchymal Stem Cell

NCT05018819

Phase 1Recruiting

Mesenchymal Stem Cells

NCT06143527

Phase 1Recruiting

Autism

NCT05003960

Phase 1Recruiting

Mesenchymal Stem Cells

NCT05147675

Clinical

Trials by Indication[1]

Mesenchymal Stem Cell12 trials

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for MS

Recruiting·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT05003388·15 enrolled

Safety of Cultured Autologous Adult Adipose Derived Mesenchymal Stem Cell Versus Cultured Allogeneic Adult Umbilical-cord Derived Mesenchymal Stem Cell Intrathecal Injection for SCI

Recruiting·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT05018793·15 enrolled

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Diabetes

Terminated·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT05003908·2 enrolled

Show 9 more trials

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Lupus

Recruiting·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT05018858·15 enrolled

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for IBD

Recruiting·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT05003947·15 enrolled

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for CKD

Recruiting·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT05018845·20 enrolled

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intrathecal Injection for ALS

Suspended·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT05003921·20 enrolled

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for RA

Recruiting·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT05003934·20 enrolled

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for TBI

Not yet recruiting·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT05018832·20 enrolled

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for IPF

Recruiting·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT05016817·20 enrolled

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Aging Frailty

Recruiting·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT05018767·86 enrolled

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for CP

Recruiting·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT05018819·15 enrolled

Mesenchymal Stem Cells6 trials

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for PCOS

Recruiting·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT06143527·20 enrolled

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for NAION

Recruiting·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT05147701·20 enrolled

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Pulmonary Diseases

Recruiting·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT05147688·20 enrolled

Show 3 more trials

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Ovarian Failure

Withdrawn·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT05158933

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for SCI

Recruiting·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT05152290·20 enrolled

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for OA

Recruiting·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT05147675·92 enrolled

5 more indications

Skin ulcer1 trial

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Skin Ulcer

Not yet recruiting·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT05158127·20 enrolled

Injury1 trial

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Testicular Injury and Oligospermia

Withdrawn·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT05158114

Osteoporosis1 trial

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Osteoporosis

Withdrawn·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT05152381

Interstitial Cystitis1 trial

Safety of Cultured Allogeneic Adult Umbilical Cord Stem Cells for Peyronie's Disease, ED, and Interstitial Cystitis

Recruiting·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT05147779·20 enrolled

Heart Disease1 trial

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Heart Disease

Terminated·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT05147766·3 enrolled

Sources

References

[1]
ClinicalTrials.gov — 26 trial records for AlloRx. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AlloRx compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AlloRx. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The Foundation for Orthopaedics and Regenerative Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: TThe Foundation for Orthopaedics and Regenerative Medicine

AlloRx

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q4 2027

Trials by Indication[1]

Mesenchymal Stem Cell12 trials

Mesenchymal Stem Cells6 trials

Autism1 trial

Tourette syndrome1 trial

Systemic Sclerosis1 trial

Skin ulcer1 trial

Injury1 trial

Osteoporosis1 trial

Interstitial Cystitis1 trial

Heart Disease1 trial

References

Drug Info

Quick Facts

Related News